A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor

Chronic Lymphocytic Leukemia Clinical Trial

Official title:

A Phase 1b/2 Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02640833
• Other study ID #: M15-330
• Secondary ID: 2015-003302-16
• Status: Withdrawn
• Phase: Phase 1
• First received: December 23, 2015
• Last updated: July 22, 2016
• Start date: July 2016
• Est. completion date: February 2021

Study information

• Verified date: July 2016
• Source: AbbVie
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This study is designed to assess the safety, pharmacokinetics, drug-drug interactions, and determine the recommended Phase 2 doses of co administered Duvelisib and Venetoclax in participants with relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, or indolent or aggressive non-Hodgkin lymphoma, who have not previously received a Bcl-2 or Phosphoinositide 3-kinase (PI3K) inhibitor. The Phase 2 portion of the study will preliminarily evaluate efficacy, and expand the toxicity evaluation.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: February 2021
• Est. primary completion date: January 2020
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria: -

Subject must have either • Relapsed or refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (for Waves 2 or 3)

• Subject has evaluable disease and requires treatment in the opinion of the investigator.

• Subject must have relapsed following or be refractory to = 1 standard treatments such as fludarabine based regimens (F, FC, FR, FCR), alkylator (chlorambucil, bendamustine) based regimens, or Bruton's Tyrosine Kinase inhibitor (Ibrutinib).

Or

• Relapsed or refractory indolent Non-Hodgkin Lymphoma or aggressive Non-Hodgkin Lymphoma (for Waves 1, 2, or 3, unless otherwise indicated)

• Subject must have histologically documented diagnosis of a Follicular Lymphoma or Marginal Zone Lymphoma.

• Subject must have histologically documented diagnosis of a Diffuse Large B-cell Lymphoma (excluding Richter's Transformation), Non-cutaneous T-Cell Lymphoma, or Mantle Cell Lymphoma (MCL) (MCL Wave 3 only)

• Subject has evaluable disease and requires treatment in the opinion of the investigator.

• Subject must have relapsed following or be refractory to = 1 standard treatments such as R-CHOP, R-CVP, bendamustine, lenalidomide-rituximab, or fludarabine-based regimens.

• Subject has an Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal to 2.

• Subject must have adequate bone marrow independent of growth factor support per local laboratory reference range at Screening.

• Subject must have adequate coagulation, renal, and hepatic function, per laboratory reference range at Screening.

• NHL subjects who have a history of an autologous stem cell transplant (e.g., bone marrow) must be > 6 months post-transplant (prior to the first dose of study drug) and must not require any growth factor support.

Exclusion Criteria:

• Subject has been previously treated with a Bcl-2 or PI3K inhibitor.

• Subject is a candidate to receive another second-line therapy approved for usage by the local Health Authority.

• Subject is appropriate for a stem cell transplant or has undergone an allogeneic stem cell transplant.

• Subject has received any of the following within 14 days or 5 drug half-lives (whichever is shortest) prior to the first dose of duvelisib or venetoclax, or has not recovered to less than Grade 2 clinically significant adverse effect(s)/toxicity(s) of the previous therapy:

• Any anti-cancer therapy including chemotherapy or radiotherapy;

• Investigational therapy, including targeted small molecule agents.

• Subject has received biologic agents (e.g., monoclonal antibodies) for anti-neoplastic treatment within 30 days prior to first dose of duvelisib or venetoclax.

• Subject has received live or live attenuated vaccines within 6 weeks prior to first dose of duvelisib or venetoclax.

• Subject has received the following within 7 days prior to the first dose of duvelisib or venetoclax:

• Steroid therapy for anti-neoplastic treatment;

• Strong and Moderate CYP3A inhibitors;

• Strong and Moderate CYP3A inducers;

• Chronic immunosuppressants, other than corticosteroids given at daily dose < 20 mg prednisone equivalent for ITP or AIHA.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Chronic Lymphocytic Leukemia
• Leukemia
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Lymphoid
• Lymphoma
• Lymphoma, Non-Hodgkin
• Non-Hodgkin Lymphoma
• Small Lymphocytic Lymphoma

Intervention

Drug:
• Duvelisib
Duvelisib will be taken continuously. This is a defining dose study, therefore the dose of Duvelisib may change.
• Venetoclax
Venetoclax will be taken continuously. This is a defining dose study, therefore the dose of Venetoclax will change.

Locations

Country	Name	City	State
United States	Site Reference ID/Investigator# 145674	Baltimore	Maryland
United States	Site Reference ID/Investigator# 145145	Boston	Massachusetts
United States	Site Reference ID/Investigator# 147922	Chicago	Illinois
United States	Site Reference ID/Investigator# 148010	Detroit	Michigan
United States	Site Reference ID/Investigator# 148561	Goshen	Indiana
United States	Site Reference ID/Investigator# 148559	Greenville	South Carolina
United States	Site Reference ID/Investigator# 148562	Harvey	Illinois
United States	Site Reference ID/Investigator# 145146	Lebanon	New Hampshire
United States	Site Reference ID/Investigator# 147747	St. Louis	Missouri
United States	Site Reference ID/Investigator# 145677	Tucson	Arizona

Sponsors (2)

Lead Sponsor	Collaborator
AbbVie	Infinity Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with adverse events	Participants will be monitored for clinical and laboratory evidence of adverse events throughout the study.	From participant's first dose until 30 days after participant's last dose of study drug; up to 2 years following last participant first dose	Yes
Primary	Maximum observed plasma concentration (Cmax) of duvelisib	The highest concentration that a drug achieves in the blood after administration in a dosing interval.	Blood samples will be taken at 0 (pre-dose) 1,2,4,6,8,10 and 12 hours post-dose on Cycle 1 Day 14 and Day 22 for second and third dose levels.	No
Primary	Maximum observed plasma concentration (Cmax) of venetoclax	The highest concentration that a drug achieves in the blood after administration in a dosing interval.	Blood samples will be taken at 0 (pre-dose) 1,2,4,6,8,10, 12 and 24 hours post-dose on Cycle 1 Days 7 and 14, and Day 22 for second and third dose levels.	No
Primary	Time to maximum observed plasma concentration (Tmax) of duvelisib	The time at which the maximum plasma concentration (Cmax) is observed.	Blood samples will be taken at 0 (pre-dose) 1,2,4,6,8,10 and 12 hours post-dose on Cycle 1 Day 14 and Day 22 for second and third dose levels.	No
Primary	Time to maximum observed plasma concentration (Tmax) of venetoclax	The time at which the maximum plasma concentration (Cmax) is observed.	Blood samples will be taken at 0 (pre-dose) 1,2,4,6,8,10,12 and 24 hours post-dose on Cycle 1 Days 7 and 14, and Day 22 for second and third dose levels.	No
Primary	Area under the plasma concentration-time curve from time 0 to 12 hours post-dose (AUC12) of duvelisib	The area under the plasma concentration-time curve over a 12-hour dose interval	Blood samples will be taken at 0 (pre-dose) 1,2,4,6,8,10 and 12 hours post-dose on Cycle 1 Day 14 and Day 22 for second and third dose levels.	No
Primary	Area under the plasma concentration-time curve from time 0 to 24 hours post-dose (AUC24) of venetoclax	The area under the plasma concentration-time curve over a 24-hour dose interval	Blood samples will be taken at 0 (pre-dose) 1,2,4,6,8,10,12 and 24 hours post-dose on Cycle 1 Days 7 and 14, and Day 22 for second and third dose levels.	No
Primary	Recommended phase two dose (RPTD) of Duvelisib in combination with venetoclax		Minimum first cycle of dosing (28 days)	Yes
Primary	Recommended phase two dose (RPTD) of Venetoclax in combination with duvelisib		Minimum first cycle of dosing (28 days)	Yes
Secondary	Progression-free survival (PFS)	Progression-free survival will be defined as the number of days from the date of study drug start to the date of documented disease progression, relapse of death due to any cause whichever occurs first.	Measured up to 2 years after the last participant has enrolled in the study	No
Secondary	Overall Response Rate (ORR)	Overall response rate will be defined as the proportion of participants who achieve a partial remission or better.	Measured up to 2 years after the last participant has enrolled in the study	No
Secondary	Time to Tumor Progression (TTP)	Time to tumor progression is defined as the number of days from the date of study drug start to the date of the first documented disease progression or relapse.	Measured up to 2 years after the last participant has enrolled in the study	No
Secondary	Duration of Response (DOR)	Duration of response is defined as the number of days from the date of documented first response of partial remission or better to the date of documented disease progression/relapse or death due to the disease whichever occurs first	Measured up to 2 years after the last participant has enrolled in the study	No